Cargando…

ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event

BACKGROUND: According to Takotsubo cardiomyopathy (TCM) diagnostic criteria, pheochromocytoma and paraganglioma (PPGL) should be excluded as secondary causes. However, it is unclear whether PPGL screening in the setting of acute TCM is reliable. We aimed to assess the prevalence of PPGL and the reli...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitton, Yoel, Bourdeau, Isabelle, Gagnon, Nadia, Legault, Jonathan, Mansour, Samer, Guay-Gagnon, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625685/
http://dx.doi.org/10.1210/jendso/bvac150.154
_version_ 1784822561772666880
author Bitton, Yoel
Bourdeau, Isabelle
Gagnon, Nadia
Legault, Jonathan
Mansour, Samer
Guay-Gagnon, Martin
author_facet Bitton, Yoel
Bourdeau, Isabelle
Gagnon, Nadia
Legault, Jonathan
Mansour, Samer
Guay-Gagnon, Martin
author_sort Bitton, Yoel
collection PubMed
description BACKGROUND: According to Takotsubo cardiomyopathy (TCM) diagnostic criteria, pheochromocytoma and paraganglioma (PPGL) should be excluded as secondary causes. However, it is unclear whether PPGL screening in the setting of acute TCM is reliable. We aimed to assess the prevalence of PPGL and the reliability of PPGL screening in a cohort of patients with TCM. Method: We retrospectively reviewed data from patients admitted in a tertiary hospital between August 2012 and January 2021 with a diagnosis of TCM proven by typical echocardiography findings and no acute occlusion on coronarography, who were screened for PPGL by plasma metanephrines/normetanephrines (M/NM). If the first screening was positive, a second plasma M/NM sample was used for confirmation. Time between TCM diagnosis and PPGL screening was collected. RESULTS: Among 64 patients identified with TCM, 42 underwent plasma M/NM screening. 81. 0% were female, and the mean age was 67.4 ± 9.9 years old. Ten patients (23.8%) had a positive result. Of those, 8 patients had a weakly positive result (1-2×upper limit of normal [ULN]) and 2 had a strongly positive result (>2×ULN). Of those 10 patients, 6 underwent a second screening: 5 had a normal result and 1 had a weakly positive result (plasma NM 1. 06×ULN). This patient underwent a third screening that was negative. In addition, an abdominal CT showed normal adrenal glands, and their chromogranin A levels were normal. Four patients had a positive initial PPGL screening, but they did not undergo a second screening: 3 died of causes unrelated to TCM before a second plasma M/NM sample was taken and one patient was lost to follow-up (his plasma NM was weakly positive at 1.29×ULN). They all had an abdominal CT that showed normal adrenal glands. Average time between TCM diagnosis and PPGL screening in all patients and in patients with a positive initial screening was 4.57 ± 3.91 and 3.38 ± 2.12 days, respectively. A linear regression model suggested an inverse relationship between plasma M/NM and time between TCM diagnosis and screening, with R2 = 0.2275. CONCLUSION: TCM occurring as the initial presentation of PPGL is rare. All patients with a positive screening ended up being false positives in our study. The ratio of false positive results when screening for PPGL in the setting of acute TCM seems to be higher than in the general population, which could be explained by a hyperadrenergic state. It is unclear whether a shorter delay between TCM diagnosis and PPGL screening may be associated with more false positives. More research is needed to determine what is the optimal timing for PPGL screening in acute TCM and if higher cut-offs should be used to minimize false positive results. Presentation: No date and time listed
format Online
Article
Text
id pubmed-9625685
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96256852022-11-14 ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event Bitton, Yoel Bourdeau, Isabelle Gagnon, Nadia Legault, Jonathan Mansour, Samer Guay-Gagnon, Martin J Endocr Soc Adrenal BACKGROUND: According to Takotsubo cardiomyopathy (TCM) diagnostic criteria, pheochromocytoma and paraganglioma (PPGL) should be excluded as secondary causes. However, it is unclear whether PPGL screening in the setting of acute TCM is reliable. We aimed to assess the prevalence of PPGL and the reliability of PPGL screening in a cohort of patients with TCM. Method: We retrospectively reviewed data from patients admitted in a tertiary hospital between August 2012 and January 2021 with a diagnosis of TCM proven by typical echocardiography findings and no acute occlusion on coronarography, who were screened for PPGL by plasma metanephrines/normetanephrines (M/NM). If the first screening was positive, a second plasma M/NM sample was used for confirmation. Time between TCM diagnosis and PPGL screening was collected. RESULTS: Among 64 patients identified with TCM, 42 underwent plasma M/NM screening. 81. 0% were female, and the mean age was 67.4 ± 9.9 years old. Ten patients (23.8%) had a positive result. Of those, 8 patients had a weakly positive result (1-2×upper limit of normal [ULN]) and 2 had a strongly positive result (>2×ULN). Of those 10 patients, 6 underwent a second screening: 5 had a normal result and 1 had a weakly positive result (plasma NM 1. 06×ULN). This patient underwent a third screening that was negative. In addition, an abdominal CT showed normal adrenal glands, and their chromogranin A levels were normal. Four patients had a positive initial PPGL screening, but they did not undergo a second screening: 3 died of causes unrelated to TCM before a second plasma M/NM sample was taken and one patient was lost to follow-up (his plasma NM was weakly positive at 1.29×ULN). They all had an abdominal CT that showed normal adrenal glands. Average time between TCM diagnosis and PPGL screening in all patients and in patients with a positive initial screening was 4.57 ± 3.91 and 3.38 ± 2.12 days, respectively. A linear regression model suggested an inverse relationship between plasma M/NM and time between TCM diagnosis and screening, with R2 = 0.2275. CONCLUSION: TCM occurring as the initial presentation of PPGL is rare. All patients with a positive screening ended up being false positives in our study. The ratio of false positive results when screening for PPGL in the setting of acute TCM seems to be higher than in the general population, which could be explained by a hyperadrenergic state. It is unclear whether a shorter delay between TCM diagnosis and PPGL screening may be associated with more false positives. More research is needed to determine what is the optimal timing for PPGL screening in acute TCM and if higher cut-offs should be used to minimize false positive results. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9625685/ http://dx.doi.org/10.1210/jendso/bvac150.154 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adrenal
Bitton, Yoel
Bourdeau, Isabelle
Gagnon, Nadia
Legault, Jonathan
Mansour, Samer
Guay-Gagnon, Martin
ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event
title ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event
title_full ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event
title_fullStr ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event
title_full_unstemmed ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event
title_short ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event
title_sort odp583 screening for pheochromocytoma in a cohort of patients with takotsubo cardiomyopathy: new insights on prevalence and screening tests reliability surrounding the acute cardiac event
topic Adrenal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625685/
http://dx.doi.org/10.1210/jendso/bvac150.154
work_keys_str_mv AT bittonyoel odp583screeningforpheochromocytomainacohortofpatientswithtakotsubocardiomyopathynewinsightsonprevalenceandscreeningtestsreliabilitysurroundingtheacutecardiacevent
AT bourdeauisabelle odp583screeningforpheochromocytomainacohortofpatientswithtakotsubocardiomyopathynewinsightsonprevalenceandscreeningtestsreliabilitysurroundingtheacutecardiacevent
AT gagnonnadia odp583screeningforpheochromocytomainacohortofpatientswithtakotsubocardiomyopathynewinsightsonprevalenceandscreeningtestsreliabilitysurroundingtheacutecardiacevent
AT legaultjonathan odp583screeningforpheochromocytomainacohortofpatientswithtakotsubocardiomyopathynewinsightsonprevalenceandscreeningtestsreliabilitysurroundingtheacutecardiacevent
AT mansoursamer odp583screeningforpheochromocytomainacohortofpatientswithtakotsubocardiomyopathynewinsightsonprevalenceandscreeningtestsreliabilitysurroundingtheacutecardiacevent
AT guaygagnonmartin odp583screeningforpheochromocytomainacohortofpatientswithtakotsubocardiomyopathynewinsightsonprevalenceandscreeningtestsreliabilitysurroundingtheacutecardiacevent